Please ensure Javascript is enabled for purposes of website accessibility

Amphastar Pharmaceuticals, inc (AMPH) Q2 2021 Earnings Call Transcript

By Motley Fool Transcribers – Aug 9, 2021 at 8:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

AMPH earnings call for the period ending June 30, 2021.

Logo of jester cap with thought bubble.

Image source: The Motley Fool.

Amphastar Pharmaceuticals, inc (AMPH 1.71%)
Q2 2021 Earnings Call
Aug 9, 2021, 5:00 p.m. ET

Contents:

  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:

Operator

Greetings and welcome to the Amphastar Pharmaceuticals' Second Quarter Earnings Call. [Operator Instructions]. A question-and-answer session will follow the formal presentation. [Operator Instructions].

All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance, backlog, sales and marketing of our products, market size and growth, product development, the timing of FDA filings or approvals, including the DMF of AMP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, our share buyback program and other future events, such as the impact of COVID-19 pandemic including its variants and related responses of business and governments to the pandemic on our operations and personnel, and on commercial activity and demand across our business operations and results of operations.

These statements are not facts, but rather are based on Amphastar's historical performance and our current expectations, estimates and projections regarding our business operations and other similar or related factors. Words such as may, might, will, could, would, should, anticipate, predict, potential, continue, expect, intend, plan, project, believe, estimate, and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words.

You should not place undue reliance on forward-looking statements, because they involve known and unknown risks, uncertainties and assumptions that are difficult or impossible to predict, and in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements, as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31st, 2020, filed with the SEC on March 15th, 2021.

In particular, the extent of COVID-19's impact on our business will depend on several factors, including the severity, duration and extent of the pandemic, including its variants, as well as actions taken by governments, businesses and consumers in response to the pandemic, all of which continue to evolve and remain uncertain at this time. You can locate these reports through our website at http://ir.amphastar.com, and on the SEC's website, at www.sec.gov.

The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available, or if subsequent events cause our expectations to change.

Please note, that this conference is being recorded. Our speakers today are Mr. Bill Peters, CFO; Mr. Dan Dischner, Vice President of Corporate Communications; and Mr. Tony Marrs, Senior Vice President of Regulatory Affairs and Clinical Operations.

I will now turn the conference over to your host, Mr. Dan Dischner, VP of Corporate Communications. Dan, you may begin.

10 stocks we like better than Amphastar Pharmaceuticals
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* 

They just revealed what they believe are the ten best stocks for investors to buy right now... and Amphastar Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of August 9, 2021

Dan Dischner -- Vice President of Corporate Communications

Thank you, Operator and thank you all for joining us this afternoon. Earlier, Amphastar reported our financial results with strong growth. As for our pipeline, I'd like to characterize the second quarter as another period in further seeing our pipeline progress. With me today is Bill Peters, Amphastar's, CFO and Executive Vice President of Finance. He will provide an update on the Company's financials. After Bill's update, we'll move to our Q&A portion of the call with Tony Marrs, Senior Vice President of Regulatory Affairs and Clinical Operations, Bill and myself.

Starting with our financial and commercial results, the second quarter saw net revenues of $101.6 million, an 18% year-over-year increase. The Company's net income remained strong and increased to $7.8 million, seeing a 56% increase from last quarter, as our one-time legal expense saw considerable savings.

While some of our products, Enoxaparin and Naloxone saw some downward pressure this quarter, we remained committed to these products in the long term, as we believe that Amphastar, being one of the few U.S. based manufacturers of these products will play in our favor due to our strengths in terms of quality. To that end, we believe our vertically integrated platform meets the needs, which call for the quality that emphasizes reliable API sourcing, supply chain resilience, and the ability to continuously meet market demands.

Looking at our newest growth driver, Glucagon, based on IQVIA, sales grew to $12.1 million for the second quarter, in line with our expectations of achieving a reasonable market share at a reasonable price. This represents a 51% increase in sales compared to last quarter, and given that sales growth remained strong, we believe Glucagon sales are well positioned to be durable for the remaining half of the year.

Regarding Primatene Mist, in store weekly sales continued an upward trend seeing a 9% increase from last quarter and a 40% increase from the same period of the previous year, thus highlighting that Primatene's success is independent of COVID-19's impact. We remain our guidance for Primatene Mist seeing annualized sales of $65 million by the end of this year. We believe that our increased distribution channels and our digital TV and radio marketing efforts have provided a stronger base of weekly sales to build upon each other.

Moreover, our marketing efforts have been complemented with our physician sampling program launched last quarter. While the sampling program results are challenging to quantify, we believe the program will be a crucial component to provide further support for Primatene to grow in the future. Moving toward our pipeline, the Company saw some upward momentum. The second quarter can be best characterized as a quarter of FDA inspections amounting to three in total; one at each of our U.S. manufacturing facilities. Two of those inspections were routine and saw zero 483 items highlighting the strength of our quality systems.

The third was a pre-approval inspection for AMP-015 which was revealed to be generic teriparatide pen for injection. As a result, teriparatide continues to be on track for a GDUFA date in the fourth quarter this year. Moreover, we have taken a conservative approach from a legal perspective, giving us the best path to commercialization as soon as we receive approval. Again, this product has no approved generics and has a plus $650 million annual market based on IQVIA.

With respect to our other filed ANDAs for AMP-002, we announced in June that the ANDA received a CRL to which it has now been fully responded to. We are awaiting the F for [Phonetic] FDA to make final determination on the GDUFA date. As a reminder, this product is a complex product with no generics and no other filers that we are aware of.

As for AMP-006, a plus $50 million annual market based on IQVIA, the ANDA is still anticipated to have a GDUFA date in the first quarter of next year. On the subject of our proprietary products, intranasal Epinephrine remains on track for a filing in 2022 as the product's clinical program continues to progress. To our other proprietary product, intranasal Naloxone, the product is progressing further in its stability studies with an expectation to refile in the fourth quarter of this year.

While we understand that an 8 milligram version was recently approved, we believe our product differentiates from others on the market. Regarding our other Paragraph-IV filings, we believe AMP-008 and our generic Regadenoson holds strong non-infringement positions. AMP-008 is still on track to be filed later this year. To close, I would like to remark that while the first interchangeable biosimilar insulin was recently approved, this has not changed Amphastar's plans regarding our insulin program. It validates our strategy. There is a pathway for interchangeable biosimilar insulin.

We continue to believe that the insulin market will remain robust. At the same time, our pipeline matures from focusing on complex injectable generics and in the [Technical Issues] with longer product life cycles, namely biosimilars and inhalation products. Considering that our existing technological platforms can already support this development demonstrated by Hyaluronidase, Enoxaparin and most recently, Glucagon, we see the pathway as clear, attainable and profitable.

I would now like to turn the call to Bill Peters to discuss our financial performance for the second quarter and give further details behind those results.

Bill Peters -- Chief Financial Officer, Treasurer, Executive Vice President of Finance, and President of Internatio

Thank you, Dan. Sales for the second quarter increased 18% to $101.7 million from $85.8 million in the previous year. Glucagon, which we launched in the first quarter has already achieved a reasonable market share at a reasonable price and led the growth with sales of $12.1 million. Primatene Mist, once again showed strong growth compared to the second quarter of last year with sales up 34% to $16.7 million from $12.5 million.

Epinephrine sales grew 32% to $9.2 million from $7 million with strong sales of the multi-dose vials. Enoxaparin saw a modest sales decline to $9.3 million as a competitor reentered the market during the second quarter. Naloxone sales declined to $6.6 million due to increased competition. Our insulin API business had sales of $6.9 million, up from $4.9 million in the prior year, primarily due to the timing of shipments, and the $0.5 million of revenues related to an amendment fee received from MannKind. We will recognize additional revenue of $250,000 per quarter related to this amendment through the end of 2022.

As we have discussed in the past, our products launched in the last few years, including Primatene Mist, Epinephrine multi-dose vials and Glucagon have margins higher than our corporate average. We showed proof of this trend this quarter with gross margins increasing to 47% of sales in the second quarter of 2021 from 39% of sales in the same quarter last year.

Selling, distribution and marketing expenses increased slightly to $4.1 million from $4 million primarily due to the marketing costs associated with our national television and radio ads, including the cost of airing our new TV commercial. General and administrative spending decreased to $14.6 million from $15.9 million primarily because of one-time expenses associated with the separation agreement with the former executive in the second quarter of last year.

Research and development expenditures increased to $18.1 million in 2021 from $16.1 million last year as we continue to develop our insulin and inhalation products. Non-operating income increased to $3.6 million from $1.3 million as we recognize the gain associated with lowering the litigation accrual for our lawsuit with Aventis which we settled at the end of the second quarter of this year. The Company reported net income attributable to Amphastar shareholders of $7.8 million or $0.16 per share in the second quarter compared to a net loss of $200,000 or $0.00 per share in the second quarter of 2020. The Company reported an adjusted net income of $10.6 million or $0.21 per share compared to an adjusted net income of $7.6 million or $0.16 per share in the second quarter of last year.

Adjusted earnings exclude amortization, equity compensation, impairments of long-lived assets and onetime events. In the second quarter, cash flow provided by operations was $32.2 million. We've repurchased $6.4 million of stock during the quarter and made $6 million in debt repayments. Today, we announced that the Board authorized an additional $20 million buyback program, which we plan to utilize in the future. We also announced that we've entered into a $140 million debt facility consisting of a $70 million term loan and a $70 million revolving line of credit. We used approximately $30 million of the term loan to pay off existing debt with higher interest rates.

We believe this facility will help us lower interest expense and ensure financial flexibility as we grow and expand our business. I will now turn the call back over to the operator to begin Q&A.

Questions and Answers:

Operator

Thank you. We will now be conducting a question-and-answer session. [Operator Instructions]. Thank you. Our first question comes from Tim Chiang with Northland Capital. Please proceed with your question.

Tim Chiang -- Northland Capital Markets -- Analyst

Hi, thanks. On AMP-015, do you guys expect multiple generics to gain approval around the same time later this year in terms of market formation for that product?

Dan Dischner -- Vice President of Corporate Communications

I'd say, it's hard to say, but I would probably side toward the answer of, no. It's a complex product that's been unchallenged for a while. So we anticipate not too many competitors with this product.

Tim Chiang -- Northland Capital Markets -- Analyst

And you guys will have enough capacity to launch this product in the fourth quarter assuming you get the approval. Is that right?

Bill Peters -- Chief Financial Officer, Treasurer, Executive Vice President of Finance, and President of Internatio

Yeah. So actually, this product will be made on one of the filling lines that we built and installed a couple of years ago. So this is part of the expansion we have at our Amphastar headquarters. So we're ready to go with this one.

Tim Chiang -- Northland Capital Markets -- Analyst

And I guess, AMP-009, that's another injectable Masteel [Phonetic] process product, but that's a Paragraph-IV. Have you -- I mean, do you already have a court date set for that or no?

Dan Dischner -- Vice President of Corporate Communications

I believe, we do have a court date set for that. And the reason that we don't list -- we don't list the GDUFA dates on the Paragraph -- ones that are constrained by Paragraph-IV is because we don't want to paint the -- make the impression that the GDUFA date is the gating item. So we do have a court date that's set for January of 2022.

Tim Chiang -- Northland Capital Markets -- Analyst

Okay. Okay, good. Maybe just one last question. It's a financial question. I mean, obviously, you took this figured term loan in revolver. Is -- I mean, I guess you have more financial flexibility, but would you have any interest in potentially pursuing some business development to bring in some additional products with some of the debt that you've now taken on?

Dan Dischner -- Vice President of Corporate Communications

Well, part of the reason that we did the debt is to refinance the existing debt. So during the quarter, we paid down $6 million of debt and $30 million of the new term loan went directly to pay off some of the existing debt. So that reduction over the past three months has been $36 million, so a little bit more than half of that.

Additionally, we had spent $30 million buying back a portion of AMP, so we wanted to keep that, put that cash back on the balance sheet for that, and we're also funding our buyback program and some large capital expenditures in the next couple of years. The debt agreement, which will be filed with our 10-Q in November does allow for acquisitions, of permitted acquisitions, but those have to be within a certain framework.

But we think that having this line in place and this revolver in place will add some flexibility and make it easier to borrow, if we do need to -- if we do see some acquisitions that we find attractive and fit well with the Company. I wouldn't say that this debt will change our attitude or toward acquisitions though.

Tim Chiang -- Northland Capital Markets -- Analyst

Right. Okay, great. Thanks. Thanks for the answers.

Dan Dischner -- Vice President of Corporate Communications

Thanks Tim.

Operator

Thank you. [Operator Instructions]. Our next question will be from David Amsellem with Piper Sandler. Please proceed with your question.

Zachary Sachar -- Piper Sandler -- Analyst

Hey, this is Zach on for David. Thanks for taking my questions and congrats on another strong quarter. So just for Primatene Mist, obviously you've done well in getting the product into the large retail chains so far. So just wondering if there are any other large retail chains that you're targeting at this point, or are you focusing more on just smaller regional channels now? And then just in terms of marketing and DTC what other investments do you plan to make for this product?

Dan Dischner -- Vice President of Corporate Communications

You know, with Primatene, I think we've hit most of the major retail distribution points. We're analyzing and looking at different smaller retail stores, maybe partnerships there. But I think right now we've hit most of the major retail. And what was the second part of the question?

Bill Peters -- Chief Financial Officer, Treasurer, Executive Vice President of Finance, and President of Internatio

Yeah. So the second part of the question dealt, I think more with some marketing of it. And I think what we would say is that our focus right now is just making sure that the consumers who have mild asthma are aware of the products. We're making -- we're spending money to make sure that everyone is aware, because we're in all the retail outlets that we need to be in that [Technical Issues] product be successful and to grow. But I think there are still people that don't know the product that well out there.

So that's what our main focus is.

Zachary Sachar -- Piper Sandler -- Analyst

Okay, great, thanks. And then if I could just squeeze in one follow-up on Epinephrine. Just wondering what kind of role you think this -- this could have in terms -- like, is this going to be mainly a retail market product or do you envision some sort of institutional footprint for it as well?

Dan Dischner -- Vice President of Corporate Communications

The nasal spray intranasal?

Zachary Sachar -- Piper Sandler -- Analyst

Yeah. The Epinephrine nasal product.

Dan Dischner -- Vice President of Corporate Communications

Well, I think it adds a different presentation to the product than what's currently there. So we'd be looking at that market, the pen market as a potential for this product.

Bill Peters -- Chief Financial Officer, Treasurer, Executive Vice President of Finance, and President of Internatio

So it is primarily we do -- primarily be a retail oriented product just like the EpiPen itself.

Dan Dischner -- Vice President of Corporate Communications

Yeah, and I think the key takeaway is, I don't think there'll be any new channel created for it, maybe it will just ease the opportunity for the ease of use for it. I think that's primarily the key to that.

Zachary Sachar -- Piper Sandler -- Analyst

Okay, great. Thanks.

Dan Dischner -- Vice President of Corporate Communications

Thank you.

Operator

Thank you. Our next question comes from Elliot Wilbur with Raymond James. Please proceed with your question.

Elliot Wilbur -- Raymond James -- Analyst

Thanks, good afternoon. Question on AMP-015. So, in your prepared commentary, Dan, you mentioned a PAI inspection for that, wasn't clear to me whether not that there were -- there were or there was 483 issued in connection with that pre-approval inspection, so just if you could clarify that. And then as a follow-up question on 015, can you confirm that this is in fact a filing that contains an auto injector device in addition to the active.

And then just a quick question for Bill on gross margin trends, obviously favorable mix benefited numbers this period, but outside of just pure mix, anything to think about in the second half of the year that might lead that number to kind of move naturally lower? Thanks.

Dan Dischner -- Vice President of Corporate Communications

Yeah, hi. As far as the PAI inspection, we've characterized it as a good inspection, and there were some 483s that were issued. They were primarily related to the timing of certain events. It didn't have any consequence or anything that really dealt with the quality system of us.

And we've fully addressed all of them. So we believe that our response will address all of the 483 issues that they've raised. And as far as the pen goes, yeah, it is an auto pen.

Bill Peters -- Chief Financial Officer, Treasurer, Executive Vice President of Finance, and President of Internatio

And I think your last question dealt with the gross margins and the trends in the second half of the year. So we think that pricing should hold relatively even for where it was in the half. We do have maybe some -- we do have some potential opportunities on a couple of products for some price increases that, that we think will be positive for the Company. But those price increases are mainly to offset some of the cost increases that we've had, cost of labor has gone up in California pretty significantly and we've had to raise our wages here.

Additionally, the price of crude heparin still has continued to go up and we -- cost of heparin on an average cost basis based on acquisition costs, and we have very long lead time for that in a lot of product in the channel. So while we actually have seen forward prices look like they're going to come down in the future, it's the average price that is used in our cost of goods will continue to go up for the next couple of quarters until we hit the -- have more that we can source more product that we [Technical Issues].

Elliot Wilbur -- Raymond James -- Analyst

That makes sense.

Operator

Thank you. Our next question comes from Serge Belanger with Needham & Company. Please proceed with your question.

Serge Belanger -- Needham & Company -- Analyst

Hey, good afternoon. Thanks for taking my questions. First one on Glucagon. Can you just talk about your -- the competitive outlook for the remainder of 2021 and 2022? And do you still expect the product to generate $40 million to $50 million this year?

Dan Dischner -- Vice President of Corporate Communications

Yeah, I think -- I think with Glucagon, it is a complex product that was off [Phonetic] -- that hadn't been challenged for a long time, we were the first ones, we don't -- at this time, we haven't seen any other potential competitors with this product the way we're marketing it or the way it's being sold now.

And the second part was the outlook into next year. I think we see more of the same. We have no reason to believe that it would be any different than it is now. Yeah.. [Speech Overlap]

Bill Peters -- Chief Financial Officer, Treasurer, Executive Vice President of Finance, and President of Internatio

Yeah, we think that the current run rate is, is good as far as we can tell for quite some time.

Dan Dischner -- Vice President of Corporate Communications

Yeah.

Serge Belanger -- Needham & Company -- Analyst

Okay. On AMP-015, obviously a complex product. What's your level of confidence if you get approval on the first review cycle?

Dan Dischner -- Vice President of Corporate Communications

Tony answer that.

Tony Marrs -- Senior Vice President, Regulatory Affairs

Well, like all complex products, it would be a surprise to have that, definitely a pleasant surprise for it. What I can say is we're positioned for it. We've learned from the other complex products that we have filed and also approved with the agency. So I think every time we file one of these applications, the contents of that application meet the requirements of its predecessor.

So, as the requirements for the agency evolve, we're keeping up with them in our filing of those applications. So I think the more that we do have these, the higher chance we have for success. But again, it would be certainly a home run for us. But we are poised for it. I think the ends [Phonetic] are moving at the speed that is encouraging as far as our correspondence with the agency and -- but I think it's just cautious optimism.

Serge Belanger -- Needham & Company -- Analyst

Okay, thank you.

Operator

Thank you. Our next question comes from David Steinberg with Jefferies. Please proceed with your question.

David Steinberg -- Jefferies -- Analyst

Thanks and good afternoon. A couple of questions. On Glucagon, you've done a really nice job in launching the product, and you made a comment that you saw the second half of the year as being, I think you said, quote-unquote, Durable. Are you implying that there'll be no sequential increases from the $12.1 million to Q3 and then Q3 to Q4, and therefore, it should be $48 million product until there is another competitor? Or do you see sequential increases?

And then secondly on 002, you got the CRL actually, the day of your Health Care Conference in early June, at the time you hadn't submitted your response. You may have had other discussions with the FDA since then, but at the time you thought, you're looking at either in October or early next year GDUFA date for 002. Is that still your thinking? Thanks.

Bill Peters -- Chief Financial Officer, Treasurer, Executive Vice President of Finance, and President of Internatio

Well, I'll take the Glucagon question first, and that is the $12.1 million -- we think that we're -- that's a pretty safe run rate pretty fair run rate. So that's what we would model at this point.

Dan Dischner -- Vice President of Corporate Communications

As far as the AMP-002, yeah, you're right, we've submitted that, and we're waiting for the agency to make a final determination of that. And as you said, the best case scenario would be based on what we believe, the best case scenario will either be later this year or early in 2022.

Operator

Thank you. There are no further questions at this time, I would like to turn the floor back over to management for any closing comments.

Dan Dischner -- Vice President of Corporate Communications

I want to thank everybody for joining us today and allowing us to give you an update on our Q2. We look forward to having another good quarter for Q3 and sharing those results with you in the future. Thank you again for your time today.

Operator

[Operator Closing Remarks].

Duration: 30 minutes

Call participants:

Dan Dischner -- Vice President of Corporate Communications

Bill Peters -- Chief Financial Officer, Treasurer, Executive Vice President of Finance, and President of Internatio

Tony Marrs -- Senior Vice President, Regulatory Affairs

Tim Chiang -- Northland Capital Markets -- Analyst

Zachary Sachar -- Piper Sandler -- Analyst

Elliot Wilbur -- Raymond James -- Analyst

Serge Belanger -- Needham & Company -- Analyst

David Steinberg -- Jefferies -- Analyst

More AMPH analysis

All earnings call transcripts

AlphaStreet Logo

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amphastar Pharmaceuticals Stock Quote
Amphastar Pharmaceuticals
AMPH
$29.18 (1.71%) $0.49

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.